ADARx Pharmaceuticals, Inc. (ADRX) Stock AnalysisADRXADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. siRNA, or small interfering RNA, therapeutics represent a significant advancement in precision medicine by addressing diseases at the genetic level (mRNA or RNA) while avoiding permanent alterations to a patient’s genome (DNA). Its hepatic-targeted programs include Agazisiran, Onvuzosiran, and ADX-626. Its extrahepatic-targeted programs include ADX-077 and ADX-199. ADX-077 is designed to reduce body weight and fat while preserving lean mass. ADX-626, is in development for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It operates in the Healthcare sector.

ADARx Pharmaceuticals is not a good buy right now due to its significant losses and declining stock performance. The current price is $13.15, which is 43.4% below its 52-week high of $23.21. Additionally, the company reported a net income loss of $25,759,000 in Q2 2026, indicating ongoing financial struggles. The main risk is its high price-to-sales ratio of 240.20, suggesting overvaluation relative to its revenue.